Mastering the Use of Systemic JAK Inhibitors for Atopic Dermatitis: A Dermatologist's Practical Guide - PubMed
12 hours ago
- #Dermatology
- #JAK Inhibitors
- #Atopic Dermatitis
- Atopic dermatitis (AD) is a common condition treated by dermatologists.
- Therapeutic options for moderate-to-severe AD include biologics and Janus kinase inhibitors (JAKis).
- Three oral JAKis are approved for AD treatment: abrocitinib, baricitinib, and upadacitinib.
- JAKis are effective but require careful patient selection and monitoring due to potential side effects.
- Side effects include increased risk of major adverse cardiovascular events (MACE) and malignancies.
- The article provides practical recommendations for prescribing and monitoring systemic JAKis for AD.
- Dermatologists need guidance on managing potential adverse reactions and clinical scenarios.